International Flavors & Fragrances Inc. (IFF) 10-Year Financial Performance & Capital Metrics

IFF • • Industrial / General

Basic MaterialsSpecialty ChemicalsAgricultural & Food ChemicalsFood Ingredients & Nutrition

AboutInternational Flavors & Fragrances Inc., together with its subsidiaries, manufactures and sells cosmetic active and natural health ingredients for use in various consumer products in Europe, Africa, the Middle East, Greater Asia, North America, and Latin America. It operates through Nourish, Scent, Health & Biosciences, and Pharma Solutions segments. The Nourish segment offers natural and plant-based specialty food ingredients, such as flavor compounds, and savory solutions and inclusions. It also provides natural food protection ingredients consist of natural antioxidants and anti-microbials as well as beverages, sweets , and dairy products. The Scent segment provides fragrance compounds, which include fine fragrances comprising perfumes and colognes, as well as consumer fragrances; fragrance ingredients comprising synthetic and natural ingredients that could be combined with other materials to create fragrance and consumer compounds; and cosmetic active ingredients consisting of active and functional ingredients, botanicals, and delivery systems to support its customers' cosmetic and personal care product lines. The Health & Biosciences segment develops and produces enzymes, food cultures, probiotics, and specialty ingredients. The Pharma Solutions segment produces and sells cellulosics and seaweed-based pharma excipients. The company sells its products primarily to manufacturers of perfumes and cosmetics, hair and other personal care products, soaps and detergents, cleaning products, dairy, meat and other processed foods, beverages, snacks and savory foods, sweet and baked goods, dietary supplements, infant and elderly nutrition, functional food, and pharmaceutical excipients and oral care products. International Flavors & Fragrances Inc. was founded in 1833 and is headquartered in New York, New York.Show more

Revenue $11.48B
EBITDA $1.78B +284.0%
Net Income $243M +109.5%
EPS (Diluted) 0.95 +109.4%
Gross Margin 35.91% +12.0%
EBITDA Margin 15.51% +283.9%
Operating Margin 6.67% +136.3%
Net Margin 2.12% +109.5%
ROE 1.7% +110.7%
ROIC 2.4% +140.8%
Debt/Equity 0.69 -6.4%
Interest Coverage 2.51 +145.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 8/9
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 17.4%
✓Healthy dividend yield of 2.8%
✓Trading at only 1.3x book value

✗Weaknesses

✗Profits declining 11.8% over 5 years
✗Dividend payout exceeds 100% of earnings

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y14.03%

5Y17.44%

3Y-0.49%

TTM-3.01%

Profit (Net Income) CAGR

10Y-5.2%

5Y-11.75%

3Y-3.21%

TTM82.23%

EPS CAGR

10Y-15.4%

5Y-24.99%

3Y-4.77%

TTM82.24%

ROCE

10Y Avg6.62%

5Y Avg-0.16%

3Y Avg-2.7%

Latest2.97%

Peer Comparison

Food Ingredients & Nutrition

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
IFFInternational Flavors & Fragrances Inc.	18.14B	70.83	74.56	0.04%	-3.72%	-2.89%	3.32%	0.69
BCPCBalchem Corporation	5.38B	166.01	42.24	3.39%	14.72%	11.5%	2.72%	0.18
SXTSensient Technologies Corporation	4.13B	97.30	33.10	6.92%	8.72%	11.79%	2.37%	0.60

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	3.02B	3.12B	3.4B	3.98B	5.14B	5.08B	11.66B	12.44B	11.48B	11.48B
Revenue Growth %	-0.02%	0.03%	0.09%	0.17%	0.29%	-0.01%	1.29%	0.07%	-0.08%	0%
Cost of Goods Sold+	1.67B	1.72B	1.93B	2.29B	3.03B	3B	7.92B	8.29B	7.8B	7.36B
COGS % of Revenue	0.55%	0.55%	0.57%	0.58%	0.59%	0.59%	0.68%	0.67%	0.68%	0.64%
Gross Profit+	1.35B	1.4B	1.47B	1.68B	2.11B	2.09B	3.73B	4.15B	3.68B	4.12B
Gross Margin %	0.45%	0.45%	0.43%	0.42%	0.41%	0.41%	0.32%	0.33%	0.32%	0.36%
Gross Profit Growth %	-0.01%	0.03%	0.06%	0.14%	0.26%	-0.01%	0.79%	0.11%	-0.11%	0.12%
Operating Expenses+	763.25M	842.61M	919.83M	1.1B	1.45B	1.52B	3.15B	5.48B	5.79B	3.36B
OpEx % of Revenue	0.25%	0.27%	0.27%	0.28%	0.28%	0.3%	0.27%	0.44%	0.5%	0.29%
Selling, General & Admin	494.52M	572.52M	570.14M	707.46M	876M	949M	1.75B	1.77B	1.79B	2B
SG&A % of Revenue	0.16%	0.18%	0.17%	0.18%	0.17%	0.19%	0.15%	0.14%	0.16%	0.17%
Research & Development	246.1M	258.86M	295.47M	311.58M	346M	357M	629M	603M	636M	671M
R&D % of Revenue	0.08%	0.08%	0.09%	0.08%	0.07%	0.07%	0.05%	0.05%	0.06%	0.06%
Other Operating Expenses	22.63M	11.23M	54.22M	79.78M	226M	214M	772M	3.11B	3.37B	692M
Operating Income+	588.35M	552.96M	552.63M	583.88M	665M	566M	585M	-1.33B	-2.11B	766M
Operating Margin %	0.19%	0.18%	0.16%	0.15%	0.13%	0.11%	0.05%	-0.11%	-0.18%	0.07%
Operating Income Growth %	-0.01%	-0.06%	-0%	0.06%	0.14%	-0.15%	0.03%	-3.27%	-0.59%	1.36%
EBITDA+	677.94M	655.42M	670.6M	757.67M	988M	891M	1.74B	-147M	-968M	1.78B
EBITDA Margin %	0.22%	0.21%	0.2%	0.19%	0.19%	0.18%	0.15%	-0.01%	-0.08%	0.16%
EBITDA Growth %	-0.01%	-0.03%	0.02%	0.13%	0.3%	-0.1%	0.95%	-1.08%	-5.59%	2.84%
D&A (Non-Cash Add-back)	89.6M	102.47M	117.97M	173.79M	323M	325M	1.16B	1.18B	1.14B	1.01B
EBIT	585.16M	576.71M	602.41M	580.32M	695M	573M	643M	-1.29B	-2.14B	583M
Net Interest Income+	-46.06M	-52.99M	-65.36M	-132.56M	-138M	-132M	-289M	-336M	-380M	-305M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	46.06M	52.99M	65.36M	132.56M	138M	132M	289M	336M	380M	305M
Other Income/Expense	-49.25M	-29.24M	-15.59M	-136.13M	-108M	-125M	-231M	-299M	-408M	-488M
Pretax Income+	539.1M	523.72M	537.04M	447.76M	557M	441M	354M	-1.63B	-2.52B	278M
Pretax Margin %	0.18%	0.17%	0.16%	0.11%	0.11%	0.09%	0.03%	-0.13%	-0.22%	0.02%
Income Tax+	119.85M	118.69M	241.38M	107.98M	97M	74M	75M	239M	45M	31M
Effective Tax Rate %	0.78%	0.77%	0.55%	0.75%	0.82%	0.83%	0.76%	1.15%	1.02%	0.87%
Net Income+	419.25M	405.03M	295.67M	334.45M	454M	365M	268M	-1.87B	-2.56B	243M
Net Margin %	0.14%	0.13%	0.09%	0.08%	0.09%	0.07%	0.02%	-0.15%	-0.22%	0.02%
Net Income Growth %	0.01%	-0.03%	-0.27%	0.13%	0.36%	-0.2%	-0.27%	-7.97%	-0.37%	1.09%
Net Income (Continuing)	419.25M	405.03M	295.67M	339.78M	460M	367M	279M	-1.86B	-2.56B	247M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	4.67M	4.89M	5.09M	92.23M	111.29M	109.43M	140M	89M	31M	35M
EPS (Diluted)+	5.16	5.05	3.72	3.83	4.00	3.20	1.10	-7.20	-10.06	0.95
EPS Growth %	0.02%	-0.02%	-0.26%	0.03%	0.04%	-0.2%	-0.66%	-7.55%	-0.4%	1.09%
EPS (Basic)	5.19	5.07	3.73	3.85	4.04	3.25	1.10	-7.20	-10.06	0.95
Diluted Shares Outstanding	80.89M	79.98M	79.37M	88.12M	113.31M	113.63M	243M	255M	255M	256M
Basic Shares Outstanding	80.45M	79.65M	79.07M	87.55M	111.97M	112.16M	243M	255M	255M	256M
Dividend Payout Ratio	0.38%	0.46%	0.7%	0.69%	0.69%	0.88%	2.49%	-	-	2.12%

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.44B	1.61B	1.9B	2.94B	2.94B	3.06B	6.99B	7.43B	6.29B	7.99B
Cash & Short-Term Investments	181.99M	323.99M	368.05M	634.9M	606.82M	650M	711M	483M	703M	469M
Cash Only	181.99M	323.99M	368.05M	634.9M	606.82M	650M	711M	483M	703M	469M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	683.07M	693M	879.05M	1.21B	1.02B	1.12B	2.21B	2.16B	2.09B	1.97B
Days Sales Outstanding	82.47	81.17	94.4	111.48	72.72	80.55	69.36	63.35	66.49	62.58
Inventory	572.05M	592.02M	649.45M	1.08B	1.12B	1.13B	2.52B	3.3B	2.64B	2.26B
Days Inventory Outstanding	124.91	125.57	123.06	171.54	135.42	137.82	115.94	145.27	123.48	111.88
Other Current Assets	-145.18M	-142.35M	-215.39M	-263.41M	77.88M	56M	1.26B	1.35B	677M	3.1B
Total Non-Current Assets+	2.26B	2.41B	2.7B	9.95B	10.34B	10.49B	32.67B	28.09B	24.68B	20.67B
Property, Plant & Equipment	732.79M	775.72M	880.58M	1.24B	1.68B	1.77B	5.16B	4.97B	4.96B	4.34B
Fixed Asset Turnover	4.13x	4.02x	3.86x	3.20x	3.06x	2.88x	2.26x	2.50x	2.32x	2.65x
Goodwill	941.39M	1B	1.16B	5.38B	5.5B	5.59B	16.41B	13.37B	10.63B	9.08B
Intangible Assets	306M	365.78M	415.79M	3.04B	2.85B	2.73B	10.51B	9.08B	8.36B	6.45B
Long-Term Investments	0	0	0	31.47M	0	5M	86M	10M	11M	10M
Other Non-Current Assets	118.39M	127.71M	149.95M	168.2M	190.2M	208M	427M	490M	449M	560M
Total Assets+	3.7B	4.02B	4.6B	12.89B	13.29B	13.56B	39.66B	35.52B	30.98B	28.67B
Asset Turnover	0.82x	0.78x	0.74x	0.31x	0.39x	0.38x	0.29x	0.35x	0.37x	0.40x
Asset Growth %	0.06%	0.09%	0.14%	1.8%	0.03%	0.02%	1.93%	-0.1%	-0.13%	-0.07%
Total Current Liabilities+	725.16M	898.3M	768.77M	1.13B	1.55B	1.9B	3.63B	3.73B	3.76B	4.33B
Accounts Payable	285.5M	274.81M	338.19M	471.38M	510.37M	556M	1.53B	1.42B	1.38B	1.28B
Days Payables Outstanding	62.34	58.29	64.08	74.97	61.54	67.69	70.59	62.44	64.5	63.63
Short-Term Debt	132.35M	258.52M	6.97M	48.64M	384.96M	634M	632M	597M	885M	1.41B
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	175.03M	129.31M	176.94M	241.4M	266.3M	115M	226M	313M	156M	485M
Current Ratio	1.98x	1.79x	2.47x	2.61x	1.90x	1.61x	1.92x	1.99x	1.67x	1.84x
Quick Ratio	1.19x	1.13x	1.62x	1.65x	1.17x	1.01x	1.23x	1.11x	0.97x	1.32x
Cash Conversion Cycle	145.04	148.45	153.38	208.05	146.6	150.68	114.7	146.18	125.46	110.83
Total Non-Current Liabilities+	1.38B	1.49B	2.14B	5.64B	5.41B	5.23B	14.8B	14.05B	12.58B	10.42B
Long-Term Debt	935.37M	1.07B	1.63B	4.5B	4B	3.78B	10.77B	10.37B	9.19B	7.56B
Capital Lease Obligations	0	0	0	0	0	265M	670M	672M	642M	534M
Deferred Tax Liabilities	0	0	51.1M	655.88M	641.46M	593M	2.52B	2.28B	1.94B	1.59B
Other Non-Current Liabilities	403.23M	380.88M	420.23M	444.24M	767.74M	594M	847M	722M	813M	733M
Total Liabilities	2.11B	2.39B	2.91B	6.76B	6.96B	7.14B	18.44B	17.78B	16.34B	14.76B
Total Debt+	1.07B	1.33B	1.64B	4.55B	4.68B	4.73B	12.2B	11.74B	10.82B	9.62B
Net Debt	885.73M	1B	1.27B	3.9B	4.05B	4.07B	11.48B	11.25B	10.11B	9.15B
Debt / Equity	0.67x	0.81x	0.97x	0.74x	0.74x	0.74x	0.57x	0.66x	0.74x	0.69x
Debt / EBITDA	1.57x	2.02x	2.44x	6.01x	4.73x	5.30x	7.01x	-	-	5.40x
Net Debt / EBITDA	1.31x	1.53x	1.90x	5.15x	4.10x	4.57x	6.60x	-	-	5.14x
Interest Coverage	12.77x	10.44x	8.45x	4.40x	4.82x	4.29x	2.02x	-3.95x	-5.55x	2.51x
Total Equity+	1.59B	1.63B	1.69B	6.13B	6.33B	6.42B	21.22B	17.74B	14.64B	13.91B
Equity Growth %	0.05%	0.02%	0.04%	2.63%	0.03%	0.01%	2.31%	-0.16%	-0.17%	-0.05%
Book Value per Share	19.72	20.39	21.28	69.51	55.85	56.50	87.33	69.58	57.42	54.34
Total Shareholders' Equity	1.59B	1.63B	1.68B	6.03B	6.22B	6.31B	21.08B	17.66B	14.61B	13.88B
Common Stock	14.47M	14.47M	14.47M	16.07M	16.07M	16.07M	35M	35M	35M	35M
Retained Earnings	3.6B	3.82B	3.87B	3.96B	4.12B	4.16B	3.64B	955M	-2.44B	-2.6B
Treasury Stock	-1.56B	-1.68B	-1.73B	-1.03B	-1.02B	-1.02B	-997M	-978M	-963M	-944M
Accumulated OCI	-613.44M	-680.1M	-637.48M	-702.23M	-716.89M	-697.54M	-1.42B	-2.2B	-1.9B	-2.53B
Minority Interest	4.67M	4.89M	5.09M	92.23M	111.29M	109.43M	140M	89M	31M	35M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	467.31M	550.14M	390.76M	437.57M	699M	714M	1.44B	397M	1.44B	1.07B
Operating CF Margin %	0.15%	0.18%	0.11%	0.11%	0.14%	0.14%	0.12%	0.03%	0.13%	0.09%
Operating CF Growth %	-0.1%	0.18%	-0.29%	0.12%	0.6%	0.02%	1.01%	-0.72%	2.62%	-0.26%
Net Income	411.67M	405.03M	295.67M	339.78M	460.27M	367.37M	279M	-1.84B	-2.56B	247M
Depreciation & Amortization	89.6M	102.47M	117.97M	173.79M	323.33M	325.36M	1.16B	1.18B	1.14B	1.01B
Stock-Based Compensation	23.16M	24.59M	26.57M	29.4M	34.48M	36M	54M	49M	65M	77M
Deferred Taxes	13.04M	14.35M	58.89M	19.4M	-59.28M	-67.72M	-236M	-294M	-369M	-304M
Other Non-Cash Items	-68.52M	-57.18M	-107.7M	2.93M	-21.35M	-20.44M	337M	2.37B	2.68B	150M
Working Capital Changes	-35.37M	46.15M	-633K	-128.6M	-38.49M	73.73M	-153M	-1.07B	485M	-115M
Change in Receivables	-91.71M	-21.54M	-68.85M	-49.96M	-9.47M	-60.98M	-169M	-117M	51M	-217M
Change in Inventory	-37.63M	15.45M	-18.91M	-117.64M	-62.13M	17.92M	-363M	-893M	605M	-34M
Change in Payables	94.52M	-7.64M	29.11M	55.14M	55.46M	27.92M	419M	-57M	-39M	40M
Cash from Investing+	-577.16M	-355.46M	-299.93M	-5.01B	-225.87M	-187M	-18M	745M	574M	326M
Capital Expenditures	-101.03M	-126.41M	-128.97M	-173.42M	-242.05M	-191.79M	-397M	-506M	-503M	-463M
CapEx % of Revenue	0.03%	0.04%	0.04%	0.04%	0.05%	0.04%	0.03%	0.04%	0.04%	0.04%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	5.17M	7.15M	19.94M	13.34M	50.07M	18.93M	18M	8M	27M	789M
Cash from Financing+	-165.03M	-34.43M	-42.56M	4.87B	-505M	-512M	-1.3B	-1.23B	-1.85B	-1.61B
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-158.87M	-184.9M	-206.12M	-230.22M	-314M	-323M	-667M	-810M	-826M	-514M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-22.01M	-21.57M	-22.12M	2.24B	-35M	-42M	-31M	-75M	-84M	-46M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	366.29M	423.73M	261.78M	264.15M	457M	522M	1.04B	-109M	936M	602M
FCF Margin %	0.12%	0.14%	0.08%	0.07%	0.09%	0.1%	0.09%	-0.01%	0.08%	0.05%
FCF Growth %	-0.02%	0.16%	-0.38%	0.01%	0.73%	0.14%	0.99%	-1.1%	9.59%	-0.36%
FCF per Share	4.53	5.30	3.30	3.00	4.03	4.59	4.28	-0.43	3.67	2.35
FCF Conversion (FCF/Net Income)	1.11x	1.36x	1.32x	1.31x	1.54x	1.96x	5.36x	-0.21x	-0.56x	4.40x
Interest Paid	46.76M	50.58M	55.44M	117.58M	134M	128M	310M	310M	370M	308M
Taxes Paid	102.73M	107.9M	107.39M	116.14M	126M	133M	289M	329M	578M	370M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	26.89%	25.11%	17.81%	8.56%	7.29%	5.73%	1.94%	-9.59%	-15.84%	1.7%
Return on Invested Capital (ROIC)	19.76%	16.22%	14.82%	6.74%	4.88%	4.06%	2.03%	-3.22%	-5.89%	2.4%
Gross Margin	44.71%	44.78%	43.32%	42.31%	41.11%	41.03%	32.04%	33.37%	32.07%	35.91%
Net Margin	13.87%	13%	8.7%	8.41%	8.83%	7.18%	2.3%	-15.02%	-22.35%	2.12%
Debt / Equity	0.67x	0.81x	0.97x	0.74x	0.74x	0.74x	0.57x	0.66x	0.74x	0.69x
Interest Coverage	12.77x	10.44x	8.45x	4.40x	4.82x	4.29x	2.02x	-3.95x	-5.55x	2.51x
FCF Conversion	1.11x	1.36x	1.32x	1.31x	1.54x	1.96x	5.36x	-0.21x	-0.56x	4.40x
Revenue Growth	-2.12%	3.08%	9.06%	17.03%	29.23%	-1.09%	129.27%	6.73%	-7.73%	0.04%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Nourish	-	-	-	-	-	-	6.26B	6.83B	6.06B	5.87B
Nourish Growth	-	-	-	-	-	-	-	9.02%	-11.26%	-3.12%
Scent	-	-	-	-	-	-	2.25B	2.3B	2.39B	2.44B
Scent Growth	-	-	-	-	-	-	-	2.09%	4.00%	1.96%
Health & Biosciences	-	-	-	-	-	-	2.33B	2.34B	2.08B	2.11B
Health & Biosciences Growth	-	-	-	-	-	-	-	0.43%	-11.03%	1.49%
Pharma Solutions	-	-	-	-	-	-	809M	971M	945M	961M
Pharma Solutions Growth	-	-	-	-	-	-	-	20.02%	-2.68%	1.69%
Flavors	1.44B	1.5B	1.63B	1.99B	2.85B	3.11B	-	-	-	-
Flavors Growth	-	3.71%	9.06%	21.98%	43.17%	9.10%	-	-	-	-
Fragrances	1.58B	1.62B	1.77B	1.5B	1.54B	1.97B	-	-	-	-
Fragrances Growth	-	2.51%	9.06%	-15.29%	3.16%	27.89%	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
EMEA	945.67M	964.93M	1.07B	1.4B	2.08B	1.99B	4.09B	4.22B	3.83B	3.84B
EMEA Growth	-	2.04%	10.43%	31.04%	49.09%	-4.53%	105.95%	3.08%	-9.13%	0.16%
North America	718.61M	769.08M	901.82M	1.01B	1.17B	1.23B	3.5B	3.85B	3.48B	3.44B
North America Growth	-	7.02%	17.26%	12.01%	15.88%	4.93%	184.88%	10.12%	-9.76%	-1.06%
Asia	839.12M	880.04M	903.55M	991.01M	1.16B	1.16B	2.73B	2.88B	2.68B	2.73B
Asia Growth	-	4.88%	2.67%	9.68%	17.35%	-0.11%	134.84%	5.43%	-6.92%	2.02%
Latin America	519.78M	502.3M	527.76M	580.08M	724.84M	706.94M	1.34B	1.49B	1.49B	1.47B
Latin America Growth	-	-3.36%	5.07%	9.91%	24.95%	-2.47%	88.98%	11.68%	-0.07%	-1.21%

Frequently Asked Questions

Valuation & Price

International Flavors & Fragrances Inc. (IFF) has a price-to-earnings (P/E) ratio of 74.6x. This suggests investors expect higher future growth.

Growth & Financials

International Flavors & Fragrances Inc. (IFF) reported $11.07B in revenue for fiscal year 2024. This represents a 297% increase from $2.79B in 2011.

International Flavors & Fragrances Inc. (IFF) grew revenue by 0.0% over the past year. Growth has been modest.

International Flavors & Fragrances Inc. (IFF) reported a net loss of $412.0M for fiscal year 2024.

Dividend & Returns

Yes, International Flavors & Fragrances Inc. (IFF) pays a dividend with a yield of 2.83%. This makes it attractive for income-focused investors.

International Flavors & Fragrances Inc. (IFF) has a return on equity (ROE) of 1.7%. This is below average, suggesting room for improvement.

International Flavors & Fragrances Inc. (IFF) generated $332.0M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...